Zhipeng Xu

Zhipeng Xu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Life Sciences
Verified
Journal Article
Closed access
DWDan Wei
Dan Wei
LLLin Liao
Lin Liao
HWHuanjun Wang
Huanjun Wang
WZWei Zhang
Wei Zhang
TWTingting Wang
Tingting Wang
ZXZhipeng Xu
Zhipeng Xu

1 January 2022 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
ZXZhipeng Xu
Zhipeng Xu
WHWenxin Hu
Wenxin Hu
BWBin Wang
Bin Wang
TXTing Xu
Ting Xu
JWJianning Wang
Jianning Wang
DWDan Wei
Dan Wei
Xu Z, et al. Yonsei Med J. 2022 Jul;63(7):619-631. https://doi.org/10.3349/ymj.2022.63.7.619

1 August 2021 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
DWDan Wei
Dan Wei
SWShaofei Wu
Shaofei Wu
JLJie Liu
Jie Liu
XZXiaoqian Zhang
Xiaoqian Zhang
XGXiaoling Guan
Xiaoling Guan
ZXZhipeng Xu
Zhipeng Xu
Theobromine, a methylxanthine present in cocoa, has been shown to possess many beneficial pharmacological properties such as anti-oxidative stress, anti-inflammatory property, and anti-microbial activity. In this study, we investigated the effects of theobromine on nonalcoholic fatty liver disease (NAFLD) and the possible underlying mechanisms in vivo and in vitro. The results showed that theobromine reduced body weight and fat mass and improved dyslipidemia. Theobromine mitigated liver injury and significantly reduced hepatic triglyceride level in mice with obesity. Histological examinations also showed hepatic steatosis was alleviated after theobromine treatment. Furthermore, theobromine reversed the elevated mRNA and protein expression of SREBP-1c, FASN, CD36, FABP4, and the suppressed expression of PPARα and CPT1a in the liver of mice with obesity, which were responsible for lipogenesis, fatty acid uptake, and fatty acid oxidation respectively. In vitro, theobromine also downregulated SREBP-1c, FASN, CD36, FABP4 and upregulated PPARα and CPT1a mRNA and protein levels in hepatocytes in a dose-dependent manner, while these changes were reversed by L-leucine, a mammalian target of rapamycin (mTOR) agonist. The present study demonstrated that theobromine improved NAFLD by inhibiting lipogenesis and fatty acid uptake and promoting fatty acid oxidation in the liver and hepatocytes, which might be associated with its suppression of mTOR signaling pathway. Novelty: Theobromine protects against high-fat diet – induced NAFLD. Theobromine inhibits lipogenesis and fatty acid uptake and promotes fatty acid oxidation in the liver and hepatocytes via inhibiting mTOR signaling pathway.

19 May 2023 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Open access
TXTing Xu
Ting Xu
DWDan Wei
Dan Wei
ZYZhe Yang
Zhe Yang
SXShanghuan Xie
Shanghuan Xie
ZYZhangbin Yan
Zhangbin Yan
JWJianning Wang
Jianning Wang
Renal cell carcinoma is one of the most common malignancies worldwide, and kidney renal clear cell carcinoma (KIRC) is the most common histopathological type of renal cell carcinoma. However, the mechanism of KIRC progression remains poorly understood. Apolipoprotein M (ApoM) is a plasma apolipoprotein and a member of the lipid transport protein superfamily. Lipid metabolism is essential for tumor progression, and its related proteins can be used as therapeutic targets for tumors. ApoM influences the development of several cancers, but its relationship with KIRC remains unclear. In this study, we aimed to investigate the biological function of ApoM in KIRC and to reveal its potential molecular mechanisms. We found that ApoM expression was significantly reduced in KIRC and was strongly correlated with patient prognosis. ApoM overexpression significantly inhibited KIRC cell proliferation in vitro, suppressed the epithelial mesenchymal transition (EMT) of KIRC cells, and decreased their metastatic capacity. Additionally, the growth of KIRC cells was inhibited by ApoM overexpression in vivo. In addition, we found that overexpression of ApoM in KIRC attenuated Hippo-YAP protein expression and YAP stability and thus inhibited KIRC growth and progression. Therefore, ApoM may be a potential target for the treatment of KIRC.

8 April 2026 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
FWFu Wen
Fu Wen
DWDan Wei
Dan Wei
WWWencai Wang
Wencai Wang
ZSZhonghua Sun
Zhonghua Sun
ZXZhipeng Xu
Zhipeng Xu
JWJianning Wang
Jianning Wang

13 February 2023 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
DWDengshuang Wu
Dengshuang Wu
ZXZhipeng Xu
Zhipeng Xu
JWJianning Wang
Jianning Wang
Objective. Clear cell renal cell carcinoma (ccRCC) is one of the common renal cell carcinomas (RCC) with a high risk of recurrence. Considering that SLC9A1 is involved in various cellular physiological processes and probably mediates the course of mTOR signaling in tumors, this study constructed a risk model for SLC9A1 combined with mTOR signaling in ccRCC, aiming at better predicting the prognosis of patients. Methods. ccRCC expression matrices were downloaded from TCGA and ICGC databases to compare the expression of SLC9A1 in TCGA, and qRT-PCR was adopted to validate the SLC9A1 expression in different RCC cells and normal kidney cells. The CIBERSORT and ESTIMATE algorithms were used to assess samples for immunity. mTOR signaling-associated genes were downloaded from the KEGG website, and then the genes were adopted to screen genes associated with SLC9A1 expression and mTOR signaling pathway colleagues, based on which univariate COX regression and lasso regression Cox analyses were conducted to construct a ccRCC prognostic risk model. ROC curves and nomograms were used to assess the validity of the models. Results. ccRCC tumor samples showed lower SLC9A1 expression than normal samples, as also evidenced by qRT-PCR. The SLC9A1 expression was highly correlated with tumor immunity. Totally, 564 key genes associated with both SLC9A1 expression and mTOR signaling were screened out, and the risk model consisting of 11 gene signatures was constructed in ccRCC based on the 564 genes. Since patients at a high risk had poorer survival outcomes, the high-risk group presented poorer immunotherapy outcomes. Moreover, a higher clinical grade of patients suggested a higher risk score. The risk score can serve as one independent prognostic factor for the prognosis prediction of ccRCC patients. Conclusion. An extremely promising prognostic indicator for ccRCC based on SLCA9A1 and mTOR signaling has been constructed to provide reference for clinical treatment.